novartis

Novartis Chief Executive Jimenez to Retire in 2018, Narasimhan Named Successor

Joseph Jimenez (l) will retire next year and be succeeded by Vasant (Vas) Narasimhan, MD.​ BASEL, Switzerland—Novartis AG (NYSE: NVS) chief executive officer Joseph Jimenez, who has led the company since 2010, announced Monday that he plans to step down as CEO in January and retire from the company on Aug. 31, 2018. The pharma company, which also owns Alcon, said its board of directors has appointed Vasant (Vas) Narasimhan, MD, the company’s global head of drug development and chief medical officer, to succeed Jimenez, effective Feb. 1, 2018. Dr. Narasimhan, a member of the company’s executive committee, joined Novartis…


Novartis to Acquire Encore Vision, Developer of Eye Drop for Treating Presbyopia

BASEL, Switzerland—Novartis announced yesterday that it has entered into a definitive agreement to acquire Encore Vision, a privately-held company in Fort Worth, Texas, that has developed eye drops for treating presbyopia. The financial details of the transaction, which is subject to regulatory approval, were not disclosed. “There is a large need for innovative, effective and safe treatment options for people with presbyopia, and there is currently no disease-modifying treatment available at all,” said Vasant Narasimhan, global head, drug development and chief medical officer, Novartis. “Novartis confirms its leadership in ophthalmology by entering another new therapy area. The addition of this…